Want to see HK:2005 full AI Analyst Report?

SSY Group (2005) Price & Analysis

6 Followers

2005 Stock Chart & Stats

HK$2.39

HK$0.03(1.26%)

At close: Jul 28 4:00 PM EDT

HK$2.39

HK$0.03(1.26%)

Day’s Range― - ―

52-Week RangeHK$2.01 - HK$3.40

Previous CloseN/A

Volume1.37M

Average Volume (3M)5.65M

Market Cap

HK$7.42B

Enterprise ValueHK$8.55K

Total Cash (Recent Filing)HK$1.82B

Total Debt (Recent Filing)HK$4.01B

Price to Earnings (P/E)15.2

Beta0.71

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.02%

Share Statistics

EPS (TTM)N/A

Shares Outstanding2,951,113,300

10 Day Avg. Volume4,536,404

30 Day Avg. Volume5,652,093

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)1.14

Price to Sales (P/S)1.99

P/FCF Ratio27.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Manageable Leverage And Expanding Asset BaseControlled leverage and sustained asset growth provide financial resilience and capacity to support operations or investment. The sizeable equity base reduces balance-sheet risk despite the recent deterioration in earnings.

Positive Operating Cash Flow And FCF RecoveryPositive operating cash flow and the return to positive free cash flow indicate that the business can generate internal funding. Although conversion varies, the 2025 recovery supports liquidity and ongoing investment capacity.

Historically Strong ProfitabilityThe multi-year record of strong margins and returns indicates an established operating model with meaningful earnings potential. This historical profitability provides a foundation for recovery if revenue and margin pressures moderate.

Bears Say

Revenue ContractionThe recent revenue decline signals weaker demand, product mix, or market execution and reduces operating leverage. If sustained, lower sales could limit scale benefits and make recovery in margins and earnings more difficult.

Material Margin CompressionThe sharp profitability reset is a fundamental concern because it indicates that reduced revenue is being accompanied by weaker economics. Persistent pressure on gross and operating margins would constrain earnings growth and cash generation.

Sharp Decline In Returns And Inconsistent Cash ConversionLower ROE shows that the enlarged equity base is producing substantially less profit, while uneven free-cash-flow conversion raises uncertainty about earnings quality. Together, these factors weaken capital efficiency and financial predictability.

SSY Group News

SSY Group Wins China Approvals for Two Key Diagnostic Injectables

An announcement from SSY Group ( ($HK:2005) ) is now available. SSY Group has secured approval from China’s...

6h ago

SSY Group Delivers Profit Growth and Higher Dividend Amid Sector Reforms

SSY Group ( ($HK:2005) ) has provided an update. SSY Group reported steady growth for the six months...

2d ago

SSY Group Declares Interim Cash Dividend for First Half of 2026

SSY Group ( ($HK:2005) ) just unveiled an update. SSY Group Limited has declared an interim ordinary cash...

2d ago

SSY Group Secures Approval for New Ozagrel Injection to Bolster Neurology Portfolio

SSY Group ( ($HK:2005) ) has provided an update. SSY Group Limited, a China-focused pharmaceutical manufacturer, has expanded...

2d ago

SSY Group Wins China Approval for Vitamin K1 Injection

SSY Group ( ($HK:2005) ) has issued an announcement. SSY Group Limited has received approval from China’s National...

8d ago

SSY Group Sets Board Meeting to Approve Interim Results and Consider Dividend

An announcement from SSY Group ( ($HK:2005) ) is now available. SSY Group Limited has scheduled a board...

13d ago

SSY Group Wins China Approval for New Antipsychotic Bulk Drug

SSY Group ( ($HK:2005) ) has shared an update. SSY Group Limited has secured approval from China’s National...

20d ago

SSY Group Wins NMPA Approvals for Four New Drugs, Bolsters Ophthalmic and ICU Portfolios

SSY Group ( ($HK:2005) ) has provided an announcement. SSY Group has secured approvals from China’s National Medical...

21d ago

SSY Group Wins Full Slate of Bids in China’s 12th National Drug Procurement Round

SSY Group ( ($HK:2005) ) has shared an announcement. SSY Group Limited announced that all 13 products with...

24d ago

SSY Group Wins NMPA Approval for New Gastrointestinal and Respiratory Drugs

An announcement from SSY Group ( ($HK:2005) ) is now available. SSY Group has received approval from China’s...

28d ago

2005 FAQ

What was SSY Group Limited’s price range in the past 12 months?

SSY Group Limited lowest stock price was HK$2.01 and its highest was HK$3.40 in the past 12 months.

What is SSY Group Limited’s market cap?

SSY Group Limited’s market cap is HK$7.42B.

When is SSY Group Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were SSY Group Limited’s earnings last quarter?

Currently, no data Available

Is SSY Group Limited overvalued?

According to Wall Street analysts SSY Group Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SSY Group Limited pay dividends?

SSY Group Limited pays a Semiannually dividend of HK$0.03 which represents an annual dividend yield of 3.02%. See more information on SSY Group Limited dividends here

What is SSY Group Limited’s EPS estimate?

SSY Group Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SSY Group Limited have?

SSY Group Limited has 2,951,113,300 shares outstanding.

What happened to SSY Group Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of SSY Group Limited?

Currently, no hedge funds are holding shares in HK:2005

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SSY Group Limited

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.